# SSX2

## Overview
SSX2 is a gene that encodes the protein SSX family member 2, which is part of the cancer/testis antigen family. This protein is primarily expressed in the testis and is involved in transcriptional regulation through interactions with other transcription regulators, despite lacking direct DNA binding motifs (Eid2013SSX2). SSX2 contains a Kruppel-associated box (KRAB) domain and a C-terminal SSX repression domain (SSXRD), both of which contribute to its role in gene regulation via epigenetic mechanisms, such as chromatin modification (Crew1995Fusion; Zöllner2015Synovial). The protein is implicated in cancer-related processes, particularly in synovial sarcoma, where it forms a fusion protein with the SYT gene, affecting gene expression and contributing to oncogenesis (Hale2019Epigenetic; de2006The). SSX2's interactions with proteins like RAB3IP and SSX2IP further suggest its involvement in cellular signaling and structural organization, highlighting its potential role in cancer pathways (de2002The).

## Structure
The SSX2 protein is composed of 188 amino acids and is characterized by a high content of charged amino acids, comprising 40-41% of its structure (dos2000Molecular; Crew1995Fusion). It contains an N-terminal region homologous to the Kruppel-associated box (KRAB) domain, which is involved in transcriptional repression (Eid2013SSX2; Crew1995Fusion). The KRAB domain is encoded by exons 4 and 5 and spans amino acids 20 to 83 (Zöllner2015Synovial). SSX2 lacks the zinc finger motifs typically associated with KRAB domains, indicating it may function through protein-protein interactions rather than direct DNA binding (Crew1995Fusion).

The C-terminal region of SSX2 includes the SSX repression domain (SSXRD), which is responsible for strong transcriptional repression and nuclear localization (dos2000Molecular; Zöllner2015Synovial). This domain also facilitates colocalization with Polycomb group proteins, suggesting a role in chromatin remodeling (Zöllner2015Synovial). SSX2 undergoes post-translational modifications, including tyrosine phosphorylation and N-glycosylation (Eid2013SSX2; Crew1995Fusion). The protein has two known isoforms, with isoform b being the most commonly studied (Eid2013SSX2).

## Function
SSX2 is a nuclear protein primarily expressed in the testis and, to a lesser extent, in the thyroid gland. It plays a significant role in transcriptional regulation, despite lacking DNA binding motifs, by interacting with other transcription regulators (Eid2013SSX2). SSX2 contains a KRAB domain and a C-terminal domain with transcription repressor activity, which are involved in gene regulation through epigenetic mechanisms, such as chromatin modification (Eid2013SSX2; Crew1995Fusion). The protein associates with the Polycomb gene-silencing complex and histones, influencing chromatin compaction and gene expression (Eid2013SSX2).

SSX2 interacts with proteins like RAB3IP and SSX2IP, which are involved in cellular signaling and structural organization (de2002The). These interactions suggest that SSX2 may play a role in cellular processes related to cancer pathways (de2002The). In synovial sarcoma, SSX2 is part of the SS18-SSX2 fusion protein, which affects gene expression through epigenetic mechanisms, including histone modifications and DNA methylation (de2006The). This fusion protein acts as a transcriptional 'activator-repressor,' impacting downstream target gene regulation (de2006The).

## Clinical Significance
The SSX2 gene is clinically significant due to its involvement in various cancers, particularly synovial sarcoma. This gene is part of a fusion event with the SYT gene, resulting in the SYT-SSX2 fusion protein, which is a hallmark of synovial sarcoma. This fusion protein affects gene expression through epigenetic mechanisms, impacting genes involved in cholesterol synthesis and those deregulated in synovial sarcomas, such as IGF2 and CD44 (de2006Thea). The presence of SYT-SSX2 fusion transcripts is detected in a significant number of synovial sarcoma cases, serving as a diagnostic marker (Crew1995Fusion).

In synovial sarcoma, tumors with the SYT/SSX2 fusion tend to have better clinical outcomes compared to those with the SYT/SSX1 fusion, as evidenced by higher metastasis-free survival rates (Panagopoulos2001Clinical). The SSX2 gene is also implicated in colon cancer, where its expression is significantly higher in cancerous tissues compared to normal tissues, suggesting its potential as a cancer-specific biomarker (Alrubie2023Higher). The expression of SSX2 in colon cancer is associated with advanced grades, indicating a role in cancer progression and metastasis (Alrubie2023Higher).

## Interactions
SSX2 interacts with several proteins, playing a role in transcriptional regulation and potentially in cancer-related processes. It directly interacts with RAB3IP, a human homolog of a Ras-like GTPase interactor, and SSX2IP, a novel nuclear protein. These interactions occur primarily through the N-terminal domain of SSX2, which includes the KRAB-like domain. RAB3IP binds specifically to SSX2 and not to other SSX family members like SSX1, SSX3, or SSX4, while SSX2IP can also interact with SSX3 (de2002The).

The interaction with RAB3IP is significant as it is normally cytoplasmic but relocates to the nucleus when coexpressed with SSX2, suggesting that SSX2 may facilitate its nuclear translocation. SSX2IP, on the other hand, is localized in the nucleus and may influence nuclear architecture (de2002The). These interactions were confirmed using yeast two-hybrid systems and GST pull-down assays, indicating direct binding in vitro (de2002The).

SSX2 is also involved in the formation of fusion proteins with the SYT gene due to chromosomal translocations in synovial sarcoma, which disrupts its normal interactions and potentially contributes to oncogenesis (Hale2019Epigenetic; Crew1995Fusion).


## References


[1. (Hale2019Epigenetic) Ryland Hale, Sami Sandakly, Janet Shipley, and Zoë Walters. Epigenetic targets in synovial sarcoma: a mini-review. Frontiers in Oncology, October 2019. URL: http://dx.doi.org/10.3389/fonc.2019.01078, doi:10.3389/fonc.2019.01078. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2019.01078)

[2. (de2006Thea) Diederik R.H. de Bruijn, Susanne V. Allander, Anke H.A. van Dijk, Marieke P. Willemse, Jose Thijssen, Jan J.M. van Groningen, Paul S. Meltzer, and Ad Geurts van Kessel. The synovial sarcoma–associated ss18-ssx2 fusion protein induces epigenetic gene (de)regulation. Cancer Research, 66(19):9474–9482, October 2006. URL: http://dx.doi.org/10.1158/0008-5472.can-05-3726, doi:10.1158/0008-5472.can-05-3726. This article has 77 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-05-3726)

[3. (dos2000Molecular) Nuno R. dos Santos, Diederik R.H. de Bruijn, and Ad Geurts van Kessel. Molecular mechanisms underlying human synovial sarcoma development. Genes, Chromosomes and Cancer, 30(1):1–14, 2000. URL: http://dx.doi.org/10.1002/1098-2264(2000)9999:9999<::aid-gcc1056>3.0.co;2-g, doi:10.1002/1098-2264(2000)9999:9999<::aid-gcc1056>3.0.co;2-g. This article has 195 citations.](https://doi.org/10.1002/1098-2264(2000)9999:9999)

[4. (Eid2013SSX2) J Eid, C Garcia, and A Frump. Ssx2 (synovial sarcoma, x breakpoint 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2013. URL: http://dx.doi.org/10.4267/2042/51817, doi:10.4267/2042/51817. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.4267/2042/51817)

[5. (Zöllner2015Synovial) Stefan K. Zöllner, Claudia Rössig, and Jeffrey A. Toretsky. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer. Cancer and Metastasis Reviews, 34(3):417–428, August 2015. URL: http://dx.doi.org/10.1007/s10555-015-9575-z, doi:10.1007/s10555-015-9575-z. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10555-015-9575-z)

[6. (Crew1995Fusion) A.J. Crew, J. Clark, C. Fisher, S. Gill, R. Grimer, A. Chand, J. Shipley, B.A. Gusterson, and C.S. Cooper. Fusion of syt to two genes, ssx1 and ssx2, encoding proteins with homology to the kruppel-associated box in human synovial sarcoma. The EMBO Journal, 14(10):2333–2340, May 1995. URL: http://dx.doi.org/10.1002/j.1460-2075.1995.tb07228.x, doi:10.1002/j.1460-2075.1995.tb07228.x. This article has 369 citations.](https://doi.org/10.1002/j.1460-2075.1995.tb07228.x)

[7. (de2002The) Diederik R.H. de Bruijn, Nuno R. dos Santos, Ellen Kater‐Baats, José Thijssen, Lieke van den Berk, Jiska Stap, Matthé Balemans, Marga Schepens, Gerard Merkx, and Ad Geurts van Kessel. The cancer‐related protein ssx2 interacts with the human homologue of a ras‐like gtpase interactor, rab3ip, and a novel nuclear protein, ssx2ip. Genes, Chromosomes and Cancer, 34(3):285–298, March 2002. URL: http://dx.doi.org/10.1002/gcc.10073, doi:10.1002/gcc.10073. This article has 47 citations.](https://doi.org/10.1002/gcc.10073)

[8. (Panagopoulos2001Clinical) Ioannis Panagopoulos, Fredrik Mertens, Margareth Isaksson, Janusz Limon, Pelle Gustafson, Björn Skytting, Måns Åkerman, Raf Sciot, Paola Dal Cin, Ignace Samson, Mariola Iliszko, Janusz Ryoe, Maria Dêbiec‐Rychter, Anna Szadowska, Otte Brosjö, Olle Larsson, Anders Rydholm, and Nils Mandahl. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes, Chromosomes and Cancer, 31(4):362–372, June 2001. URL: http://dx.doi.org/10.1002/gcc.1155, doi:10.1002/gcc.1155. This article has 102 citations.](https://doi.org/10.1002/gcc.1155)

[9. (de2006The) Diederik R.H. de Bruijn, Susanne V. Allander, Anke H.A. van Dijk, Marieke P. Willemse, Jose Thijssen, Jan J.M. van Groningen, Paul S. Meltzer, and Ad Geurts van Kessel. The synovial sarcoma–associated ss18-ssx2 fusion protein induces epigenetic gene (de)regulation. Cancer Research, 66(19):9474–9482, October 2006. URL: http://dx.doi.org/10.1158/0008-5472.can-05-3726, doi:10.1158/0008-5472.can-05-3726. This article has 77 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-05-3726)

[10. (Alrubie2023Higher) Turki M. Alrubie, Abdullah M. Alamri, Bader O. Almutairi, Abdulwahed F. Alrefaei, Maha M. Arafah, Mohammad Alanazi, Abdelhabib Semlali, and Mikhlid H. Almutairi. Higher expression levels of ssx1 and ssx2 in patients with colon cancer: regulated in vitro by the inhibition of methylation and histone deacetylation. Medicina, 59(5):988, May 2023. URL: http://dx.doi.org/10.3390/medicina59050988, doi:10.3390/medicina59050988. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/medicina59050988)